UnknownNot Applicable

DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients

China300 participantsStarted 2021-01-22

Plain-language summary

Kidney transplantation is the best therapy method for patients with uremia. The main factors affecting the long-term survival of the graft were chronic antibody-mediated rejection and the death of the patients. Newborn donor special antibody (DSA) is a major risk factor for chronic antibody-mediated rejection (AMR) and poor transplantation outcomes. Detection of mycophenolate mofetil (MMF) trough concentration can help estimate its exposure. Deficient exposure of MMF can lead to AMR after transplantation surgery. The aim of this study is to estimate the risk factors of one-year DSA after transplantation.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * years 18-65 * single organ transplantation * first time to accept kidney transplantation * Triple immunosuppression protocol based on MMF, tacrolimus and glucocorticoid * PRA negative before transplantation * not pregnant for female Exclusion Criteria: * Not accept MMF * multi-organ transplantation * pregnancy or lactation period female * mental illness * past tumor, peptic ulcer, severe cardiopulmonary disease, active liver disease history * Cannot regular follow up

What they're measuring

DSA 12 month

Timeframe: 2021.5-2023.5

Trial details

NCT IDNCT04368962

SponsorFirst Affiliated Hospital Xi'an Jiaotong University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-22

Contact for this trial

Wujun Xue, Prof.

+86 13991990128 xwujun163@mail.xjtu.edu.cn

View on ClinicalTrials.gov More Antibody-mediated Rejection trials